Management of metabolic-associated fatty liver disease: The diabetology perspective

doi:10.3748/wjg.v29.i1.126

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 29, Issue 1

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (5138)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-3) series, Tables (1-1) series.

Item

Count

PDF

292

WORD

HTML

3426

Figures (1-3)

262

Tables (1-1)

230

Sum=4251

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

224

Download

200

Sum=424

Publishing Process of This Article

Item

Count

Browse

185

Download

278

Sum=463

Jan 7, 2023 (publication date) through Apr 23, 2024

Times Cited of This Article

Times Cited (12)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Minireviews

World J Gastroenterol. Jan 7, 2023; 29(1): 126-143
Published online Jan 7, 2023. doi: 10.3748/wjg.v29.i1.126

Full Size Figure Download Figure

Figure 1 Pathobiological link between metabolic-associated fatty live disease and type 2 diabetes mellitus. Metabolic-associated fatty live disease (MAFLD) may increase the risk for hyperglycemia and dyslipidemia and cause β-cell dysfunction leading to insulin resistance and type 2 diabetes which in turn may aggravate MAFLD progression to nonalcoholic steatohepatitis and fibrosis. IR: Insulin resistance; MAFLD: Metabolic-associated fatty live disease; TG: Triglycerides.

Citation: Jeeyavudeen MS, Khan SKA, Fouda S, Pappachan JM. Management of metabolic-associated fatty liver disease: The diabetology perspective. World J Gastroenterol 2023; 29(1): 126-143
URL: https://www.wjgnet.com/1007-9327/full/v29/i1/126.htm
DOI: https://dx.doi.org/10.3748/wjg.v29.i1.126